Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is indicated for adults. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil, combined with hydrochlorothiazide, is used in cardiovascular therapy to control blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Heart failure adjunct: assists in fluid management when used with other heart‑failure therapies. - Diabetic nephropathy risk reduction: helps delay progression of kidney damage associated with diabetes by controlling hypertension. - Stroke prevention: contributes to reduced risk of stroke in patients with high blood pressure. - Chronic kidney disease support: aids in blood‑pressure control for patients with mild to moderate chronic kidney disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema involving face, lips or airway - Liver function abnormalities - Blood cell disorders such as neutropenia

When prescribing Olmesartan Medoxomilo + Hidroclorotiazida, clinicians should consider several safety aspects.

- Renal function: assess baseline creatinine and monitor periodically. - Electrolyte balance: check serum potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant drugs: review for potential interactions that affect potassium or renal function. - Hypersensitivity: discontinue if angio‑edema or severe rash develops. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxomilo + Hidroclorotiazida may interact with several medicines, requiring clinical awareness.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Aliskiren (in diabetic patients): increased risk of renal impairment and hypotension. - NSAIDs (high‑dose or chronic use): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Lithium: possible increase in lithium levels. - Antidiabetic agents: enhanced glucose‑lowering effect, monitor blood sugar. - Other antihypertensives: additive blood‑pressure lowering, watch for hypotension.